Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 104 results
      PP405 Identity Research

      community PP405 Identity Research

      in Research  292 upvotes 1 year ago
      PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

      community Possible natural pp405 solution

      in Research/Science  45 upvotes 1 year ago
      Rotenone, a natural plant extract, may promote hair growth by increasing LDH activity and blocking MPC in the scalp, but it carries risks due to its toxicity. The suggested formulation includes Barbasco extract, DMSO, propylene glycol or PEG-400, ethanol, and a carrier oil.

    Learn

    1 / 800 results

      learn PP405

      mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
      • Can PP405 help bald patches caused by stress? PP405 is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier; its registered Phase 2 trial (NCT06393452) tested it once daily in 78 adults with pattern hair loss, for safety and tolerability. It is not approved, not for sale, and has not been studied in alopecia areata or stress-related shedding.
      • Can applying a mask with PP405 directly to thinning areas give your scalp the push it needs? No PP405 mask exists to test: PP405 is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier, it is not an anti-DHT ingredient, and it is not on sale. Its registered Phase 2 trial (NCT06393452) measured safety, not regrowth, and a rinse-out mask is in any case the wrong format for reaching the follicle.
      • Is PP405 a peptide that protects follicles from DHT? PP405 is not a peptide and does not block DHT: it is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier, aimed at waking dormant follicles. Its registered Phase 2 trial (NCT06393452) measured safety and tolerability in 78 adults with pattern hair loss; it is not approved and not for sale.